Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Inspire Investing LLC

Inspire Investing LLC lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 77.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,986 shares of the biopharmaceutical company’s stock after selling 33,538 shares during the quarter. Inspire Investing LLC’s holdings in Royalty Pharma were worth $263,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Swedbank AB boosted its position in shares of Royalty Pharma by 30.6% during the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock worth $285,151,000 after purchasing an additional 2,533,570 shares during the period. New South Capital Management Inc. boosted its position in shares of Royalty Pharma by 60.7% during the second quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company’s stock worth $61,943,000 after buying an additional 887,522 shares during the period. Homestead Advisers Corp boosted its position in shares of Royalty Pharma by 40.7% during the first quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock worth $57,502,000 after buying an additional 547,000 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Royalty Pharma by 10.4% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,856,998 shares of the biopharmaceutical company’s stock valued at $56,396,000 after buying an additional 175,261 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Royalty Pharma by 6.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,533,094 shares of the biopharmaceutical company’s stock worth $40,428,000 after acquiring an additional 86,248 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX opened at $27.71 on Wednesday. The company has a market cap of $16.55 billion, a PE ratio of 20.68, a P/E/G ratio of 4.17 and a beta of 0.46. The company’s 50 day moving average is $28.02 and its two-hundred day moving average is $27.96. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period last year, the firm earned $0.85 earnings per share. Equities analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Wall Street Analyst Weigh In

Several research firms have weighed in on RPRX. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley upped their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.